Breast Cancer clinical trials in West Virginia

5 actively recruiting breast cancer trials at 8 sites across West Virginia.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05929768

Sites in West Virginia:

United Hospital Center — Bridgeport, West Virginia
WVUH-Berkely Medical Center — Martinsburg, West Virginia
West Virginia University Healthcare — Morgantown, West Virginia
Camden Clark Medical Center — Parkersburg, West Virginia
Princeton Community Hospital — Princeton, West Virginia

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT06876714

Sites in West Virginia:

United Hospital Center — Bridgeport, West Virginia
Edwards Comprehensive Cancer Center — Huntington, West Virginia
Saint Mary's Medical Center — Huntington, West Virginia
WVUH-Berkely Medical Center — Martinsburg, West Virginia
West Virginia University Healthcare — Morgantown, West Virginia

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…

Sponsor: AstraZeneca

NCT ID: NCT05952557

Sites in West Virginia:

Research Site — Charleston, West Virginia
Research Site — Morgantown, West Virginia

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…

Sponsor: Hoffmann-La Roche

NCT ID: NCT06065748

Sites in West Virginia:

West Virginia University Hospitals Inc — Morgantown, West Virginia

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05564377

Sites in West Virginia:

West Virginia University Charleston Division — Charleston, West Virginia
Edwards Comprehensive Cancer Center — Huntington, West Virginia
West Virginia University Healthcare — Morgantown, West Virginia

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20